Background Type 2 myocardial infarction (MI) is defined by a rise and fall of cardiac biomarkers and evidence of ischemia without unstable coronary artery disease (CAD) because of a mismatch in myocardial oxygen supply and demand. Myocardial injury is similar but does not fulfill the clinical criteria for MI. There is uncertainty in terms of the clinical characteristics, management, and outcomes of type 2 MI and myocardial injury in comparison with type 1 MI.
Introduction
According to the Universal Definition of Myocardial Infarction (MI), the diagnosis of MI requires the rise and/ or fall of cardiac biomarkers with clinical evidence of ischemia, defined by symptoms, ECG changes, or new regional wall motion abnormalities. Since 2007, this definition has classified MI into five distinct subtypes [1] . In contrast to MI because of an acute coronary syndrome (type 1 MI), type 2 MI is defined as a mismatch in myocardial oxygen supply and demand that is not attributed to unstable coronary artery disease (CAD). Type 2 MI has been reported in 2-25% of cases of MI depending on the population studied and the sensitivity of the cardiac biomarker assay [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] . Although type 2 MI has been described formally for a decade, there remains considerable uncertainty as to its pathogenesis, provoking factors, optimal medical management, and long-term outcomes [2, 12] . Myocardial injury without definite MI, defined by a rise and/or a fall in cardiac biomarkers that does not fulfill the Universal Definition criteria for MI, has also increasingly been recognized as a significant entity. Myocardial injury is well characterized in the postoperative period following noncardiac surgery and is associated strongly with short-term mortality [3, 13, 14] . The aim of the present study was to evaluate the clinical characteristics, medical treatment, and intermediate-term cardiovascular outcomes of all patients admitted to a large urban Veterans Affairs (VA) hospital with abnormal cardiac biomarkers by myocardial injury and MI subtype.
Patients and methods
All patients admitted to the US Department of Veterans Affairs New York Harbor Healthcare System (a tertiary care hospital and regional referral center for cardiac surgery and percutaneous coronary intervention) from 1 October 2012 to 31 October 2013 with at least one Supplemental digital content is available for this article. Direct URL citations appear in the printed text and are provided in the HTML and PDF versions of this article on the journal's website (www.coronary-artery.com).
abnormal serum cardiac troponin I (cTnI) laboratory value were identified by an automated electronic alert sent to the chief of cardiology. Plasma cTnI was measured using the Troponin-Ultra assay (Siemens Healthcare Diagnostics, Erlangen, Germany), with a normal reference range from 0.006 to 0.06 ng/ml. According to clinical protocol, all patients with at least one abnormal cTnI value were required to have a cardiology consultation within 24 h of hospital admission. The study was approved by the VA New York Harbor Healthcare System Institutional Review Board with a waiver of informed consent.
Patients with a greater than or equal to 20% rise and/or fall of cTnI were stratified by the presence of symptoms or signs of ischemia. Patients with symptoms or signs of ischemia were classified into MI subtypes one through five as per the Universal Definition of MI [1] . Patients with myocardial injury without evidence of ischemia that occurred in a clinical scenario with a mismatch in oxygen supply and demand were classified as having myocardial injury without definite MI. All other elevations in cTnI that did not fulfill the criteria for MI and without a clinically evident mismatch in oxygen supply and demand were classified as nonspecific elevations in troponin (e.g. chronic cTnI elevation in the setting of renal disease) and were excluded from the primary analysis. An algorithmic approach to the classification of MI and myocardial injury is shown in the Supplementary Fig. 1 (Supplemental digital content 1, http://links.lww.com/MCA/ A163). Classification of myocardial injury and MI was performed on the basis of review of all clinical documentation, ECGs, cardiovascular imaging, and the impression of the consulting cardiologist.
Baseline, treatment, and outcome variables were collected by review of the medical record. Provoking conditions associated with a mismatch in myocardial oxygen supply and demand were identified. Conditions associated with decreased myocardial oxygen supply were hypotension, anemia, bradyarrhythmia, and respiratory failure. Tachycardia, tachyarrhythmias, severe hypertension, and sepsis were associated with increased myocardial oxygen demand. Hypotension was defined as a systolic blood pressure less than 90 mmHg or a mean arterial pressure less than 65 mmHg. Anemia was defined as hemoglobin less than 7 g/dl or recent bleeding or hemorrhage. Respiratory failure was defined by the administration of high flow oxygen, application of noninvasive positive pressure ventilation, or urgent/emergent intubation with mechanical ventilation. Tachycardia and bradycardia were recorded as a provoking condition when the cardiac arrhythmia was suspected as an etiology of myocardial ischemia by the treating physician. Severe hypertension was defined as a systolic blood pressure greater than 180 mmHg or a diastolic blood pressure greater than 110 mmHg. Sepsis was defined as an infectious illness that fulfilled systemic inflammatory response syndrome criteria. The results of cardiovascular testing, including echocardiography and coronary angiography, were obtained. Obstructive CAD was defined as any lesion with at least 50% angiographic stenosis. Medications prescribed at hospital discharge were identified for surviving patients.
The primary outcomes of interest were defined as allcause and cardiovascular mortality assessed through 12 May 2015 (median follow-up of 1.8 years). The secondary outcomes of interest included in-hospital mortality and hospital readmission to VA medical centers. Readmissions were further classified as hospitalization for MI and acute decompensated heart failure on the basis of the primary indication for hospital admission as per clinical discharge documentation. All deaths were classified as cardiovascular or noncardiovascular on the basis of review of VA clinical documentation.
Normally distributed continuous data are shown as mean SD and compared using an independent sample t-test. Skewed continuous data are presented as median (interquartile range) and compared using the Mann-Whitney test. Categorical variables are presented as n (proportion) and compared using the Fisher exact test or the χ 2 -test. Kaplan-Meier curves were generated to determine intermediate-term survival, with between-group comparisons performed using the log rank test. Cox proportional hazard models were used to evaluate predictors of intermediate-term mortality after adjustment for demographic and key clinical variables. Models included age, sex, race, tobacco use, chronic obstructive pulmonary disease, hypertension, hyperlipidemia, diabetes mellitus, chronic kidney disease, end-stage renal disease, previous MI, previous coronary revascularization, heart failure, peripheral artery disease, malignancy, peak troponin during hospitalization, MI or myocardial injury subtype, and aspirin and statin prescription at hospital discharge as covariates. Two-sided P values less than 0.05 were considered to be statistically significant for all tests. Statistical analyses were carried out using SPSS 20 (IBM SPSS Statistics, Armonk, New York, USA).
Results
Of the 768 patients admitted to the VA New York Harbor Healthcare System with at least one cTnI measurement above the 99% upper reference limit of the laboratory assay, 710 (92.4%) patients had an at least 20% rise and fall in cTnI. Table 1 . Overall, the average age of the patients was 73.5 12.4 years, 98.6% were men, and 56.8% were White. Cardiovascular risk factors were prevalent in all groups. Peak serum cTnI levels were higher among patients with type 1 MI than type 2 MI and higher among patients with type 2 MI than myocardial injury without MI. Patients with type 2 MI were less likely to have chest pain or ischemic symptoms than patients presenting with type 1 MI, but there was no difference in the proportions with ischemic ECG changes between these two groups (Table 1) .
Provoking conditions associated with type 2 MI and myocardial injury are shown in Table 1 . Overall, tachyarrhythmia (34.3%), severe hypertension (21.8%), and anemia (19.9%) were the most common provoking conditions associated with a mismatch in myocardial oxygen supply and demand. Noncardiac surgery was a provoking condition of myocardial injury or type 2 MI in 11.8% of cases. Among patients with any myocardial injury after noncardiac surgery, only 21% (8/38) met the universal definition for type 2 MI. Multiple provoking conditions were identified in 41% of patients with type 2 MI or myocardial injury without definite MI.
The results of in-hospital cardiovascular diagnostics are shown in Table 2 . Coronary angiography was more common among patients with type 1 MI versus type 2 MI (83.2 vs. 13.0%, P < 0.0001), but not significantly different between type 2 MI and myocardial injury. At hospital discharge, survivors of type 1 MI were more likely to receive aspirin, statin, and dual antiplatelet therapy at discharge in comparison with type 2 MI patients. There was no significant difference in the proportion of survivors of type 2 MI who were prescribed aspirin, statin, and dual antiplatelet therapy compared with survivors of myocardial injury ( Table 3) .
The clinical outcomes for the study cohort are shown in Among patients who survived to hospital discharge, a total of 199 (62.1%) patients were re-hospitalized at a VA healthcare facility over the course of follow-up. The rates of all-cause re-hospitalization, re-hospitalization for heart failure, and re-hospitalization for MI were high in patients with type 1 MI, type 2 MI, and myocardial injury during intermediate-term follow-up (Table 4) . 
Discussion
In this study of patients who presented to a large VA tertiary care hospital in New York City, a greater proportion of patients with type 1 MI underwent coronary angiography and received guideline-directed medical therapy (GDMT) for CAD at discharge compared with those with type 2 MI or myocardial injury without MI. After 1.8 years of follow-up, no significant differences in intermediate-term all-cause mortality were identified among patients with type 2 MI and myocardial injury in comparison with type 1 MI, even after multivariable adjustment for demographics, clinical presentation, and discharge medications.
Clinical features were similar among patients with type 2 MI and myocardial injury without definite MI, suggesting a considerable overlap between these diagnoses. As distinctions between type 2 MI and myocardial injury are particularly challenging when clinical symptoms of ischemia cannot be reliably detected, such as after surgery, proposals for a revised Universal Definition of type 2 MI have garnered increased attention [3, 13, 15] .
Among patients who survived the index hospitalization, patients with type 2 MI and myocardial injury were less likely to receive GDMT for CAD, including aspirin or statin, than patients with type 1 MI. These data suggest that clinical providers remain uncertain about the benefits of conventional GDMT in the treatment of myocardial injury or MI precipitated by mismatch in myocardial oxygen supply and demand. Similarly, few patients with type 2 MI (13.0%) and myocardial injury (10.9%) underwent coronary angiography, and both groups were less likely to undergo coronary angiography than type 1 MI (83%). This may reflect advanced age, a higher burden of concomitant noncardiac illness, or lower cTnI values in patients with type 2 MI or myocardial injury in comparison with patients presenting with type 1 MI. However, the rates of percutaneous coronary interventions were similar among patients with type 1 MI, type 2 MI, and myocardial injury who were referred for angiography. This suggests that type 2 MI and myocardial injury patients may be under-referred for invasive Survival of patients with type 1 myocardial infarction (MI), type 2 MI, and myocardial injury without definite MI. The overall log rank P value is 0.94 for three-way comparison. Log rank P value is 0.81 for type 1 MI versus type 2 MI; log rank P value is 0.74 for type 2 MI versus myocardial injury.
evaluation of CAD, and there may be a large burden of under-diagnosed CAD in these subgroups. Still, it remains uncertain whether differences in diagnostic cardiovascular testing and GDMT negatively impact patients with type 2 MI and myocardial injury.
Outcomes for patients with type 2 MI and myocardial injury in this analysis were poor, with~10% in-hospital mortality and 30% all-cause mortality at a median of 1.8-year follow-up. These data are comparable to previous reports of long-term outcomes after type 2 MI [5, 7] . Importantly, all-cause mortality did not differ between MI subtypes in the present analysis, and the rates of cardiovascular morbidity and mortality were high in all groups. Although a few previous studies have also reported no significant differences in outcomes among MI subtypes [16, 17] , others report significantly higher long-term mortality in patients with type 2 MI than those with type 1 MI [5, 7, [18] [19] [20] . Many of these studies were carried out outside the USA with relatively small cohorts [5, 19, 20] . There are a few notable limitations to the present study.
Although clinical data and ECGs were available for indepth medical record review, misclassification bias is possible, especially in terms of the subtle distinctions between type 2 MI, myocardial injury without definite MI, and nonspecific elevations in troponin. Indeed, lower use of echocardiography in myocardial injury may represent a missed opportunity to identify new wall motion abnormalities consistent with type 2 MI. However, as an ongoing institutional quality initiative, all patients with at least one abnormal cTnI were prospectively evaluated by a consultant in cardiovascular disease to determine the mechanism of myocardial injury. Still, variability in clinical presentations and perceived severity of illness may bias approaches to treatment, particularly among patients with type 2 MI and myocardial injury. Second, although the VA New York Harbor Healthcare System serves a large and diverse urban area, the sample size of patients with an abnormal cTnI was relatively small, and few patients with STEMI were included. However, given the high-risk nature of the population, the number of adverse events, including death, was high. Third, because of the demographics of the overall population of military veterans, few women were included in this analysis. Fourth, despite the availability of intermediate-term mortality, data from non-VA facilities on re-hospitalization or subsequent cardiovascular testing were not available for analysis, and as a consequence, re-hospitalization rates may be under-reported.
Conclusion
Among patients admitted to an urban VA hospital network, an abnormal rise and fall of cTnI was attributed to type 2 MI or myocardial injury without definite MI in 45% of cases. Patients with type 2 MI and myocardial injury without definite MI were less likely to receive guideline-directed medical therapy for CAD than patients with type 1 MI. No significant differences in intermediate-term all-cause mortality between patients with type 1 MI, type 2 MI, and myocardial injury were observed, even after multivariable adjustment for demographics, clinical covariates, and medical therapy. The rates of cardiovascular morbidity and mortality were high in all subgroups. Ultimately, additional studies to determine long-term benefits of intensive GDMT and coronary revascularization for atherosclerotic cardiovascular disease in the high-risk population of patients with type 2 MI and myocardial injury are warranted.
